TY - JOUR
T1 - Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G2/M checkpoint
AU - Aytac, Ugur
AU - Sato, Kazuya
AU - Cabanillas, Fernando
AU - Dang, Nam H.
AU - Ho, Linus
AU - Claret, Francois Xavier
AU - Mills, Gordon B.
AU - Dang, Nam H.
AU - Ohnuma, Kei
AU - Morimoto, Chikao
PY - 2001/10/1
Y1 - 2001/10/1
N2 - CD26, a Mr 110,000 surface-bound ectopeptidase with dipeptidyl peptidase IV (DPPIV) activity, has an array of diverse functional properties, with a role in T-cell physiology and the development of certain human cancers. In this study, we report that surface expression of CD26, through its associated DPPIV enzyme activity, enhanced sensitivity of Jurkat T-cell transfectants to G2-M arrest induced by the chemotherapeutic drug, doxorubicin. This was associated with disruption of cell cycle-related events, including hyperphosphorylation and inhibition of p34cdc2 kinase activity, phosphorylation of cdc25C, and alteration in cyclin B1 expression. In addition, we demonstrate that the addition of exogenous soluble DPPIV enhanced sensitivity of lymphoid tumor cell lines to doxorubicin, suggesting a potentially useful clinical role for CD26/DPPIV in the treatment of selected human hematological malignancies.
AB - CD26, a Mr 110,000 surface-bound ectopeptidase with dipeptidyl peptidase IV (DPPIV) activity, has an array of diverse functional properties, with a role in T-cell physiology and the development of certain human cancers. In this study, we report that surface expression of CD26, through its associated DPPIV enzyme activity, enhanced sensitivity of Jurkat T-cell transfectants to G2-M arrest induced by the chemotherapeutic drug, doxorubicin. This was associated with disruption of cell cycle-related events, including hyperphosphorylation and inhibition of p34cdc2 kinase activity, phosphorylation of cdc25C, and alteration in cyclin B1 expression. In addition, we demonstrate that the addition of exogenous soluble DPPIV enhanced sensitivity of lymphoid tumor cell lines to doxorubicin, suggesting a potentially useful clinical role for CD26/DPPIV in the treatment of selected human hematological malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0035477462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035477462&partnerID=8YFLogxK
M3 - Article
C2 - 11585756
AN - SCOPUS:0035477462
SN - 0008-5472
VL - 61
SP - 7204
EP - 7210
JO - Cancer Research
JF - Cancer Research
IS - 19
ER -